세계의 토포이소머라제 I 억제제 시장 보고서(2025년)

Topoisomerase I Inhibitors Global Market Report 2025

US $ 4,490 ￦ 6,253,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,490 ￦ 9,039,000

PDF (Site License)

PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,490 ￦ 11,824,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

토포이소머라제 I 억제제 시장 규모는 향후 몇 년 동안 강력한 성장세를 보일 것으로 예상되며, 2029년에는 6.0%의 CAGR로 69억 5,000만 달러에 달할 것으로 예상됩니다. 예측 기간 동안의 성장은 암 발병률 증가, 연구개발 확대, 암 치료 옵션에 대한 인식 증가, 고령화, 암 연구에 대한 정부 자금 지원 증가 등에 기인할 것으로 보입니다. 이 기간 동안 예상되는 주요 동향으로는 유전체 및 맞춤의료의 발전, 경구용 제제 개발, 병용요법의 효과 향상, 제네릭 의약품 개발, 민관 협력의 증가 등이 있습니다.

암의 유병률 증가는 가까운 장래에 토포이소머라제 I 억제제 시장을 크게 견인할 것으로 예상됩니다. 암은 비정상적인 세포의 무질서한 증식과 확산으로 정의되는 질병군으로 사망을 포함한 심각한 건강 합병증을 유발할 수 있습니다. 암 환자의 증가는 식습관 장애, 운동 부족, 담배 사용과 같은 생활습관 관련 위험요인의 증가와 관련이 있으며, 이 모든 것이 암 발병률 증가에 기여하고 있습니다. 토포이소머라제 I 억제제는 암세포의 DNA 복제 과정을 억제하여 DNA 손상을 일으켜 세포분열을 멈추고 세포 사멸을 유도함으로써 암 치료에 사용됩니다. 예를 들어, 2024년 2월 세계보건기구(WHO)는 2050년까지 3,500만 명 이상의 암 환자가 새로 발생해 2022년 예상했던 2,000만 명에서 77% 증가할 것으로 예측했습니다. 이러한 암 환자 급증은 토포이소머라제 I 억제제 시장 성장에 중요한 촉진제가 될 것입니다.

토포이소머라제 I 억제제 시장의 주요 업체들은 항체의 표적화 능력을 활용하여 약제 내성을 극복하는 항체약물접합체(ADC)와 같은 시장을 개척하는 데 주력하고 있습니다. 암세포에 직접 전달합니다. 예를 들어, 2024년 7월 캐나다에 본사를 둔 생명공학 기업 자이메웍스(Zymeworks)는 미국 식품의약국(FDA)이 ZW191의 임상시험용 신약(IND) 신청을 승인했다고 발표했습니다. 이 혁신적인 ADC는 엽산 수용체 a(FRa)를 표적으로 하는 토포이소머라제 I 억제제(TOPO1i)를 전달하며, ZW191은 첨단 TOPO1i 기반 페이로드 기술인 ZD06519를 통합한 자이메웍스의 독자적인 약물 복합체 플랫폼을 통해 개발됐습니다. ZW191은 주로 난소암 및 기타 부인과 암, 비소세포폐암(NSCLC)을 포함한 FRa 발현 종양을 표적으로 합니다. 이 약은 안전성과 유효성을 최적화하기 위해 8가지 약물 항체 비율(DAR)로 설계되었으며, 내약성과 치료 효과의 균형을 맞추기 위해 노력하고 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 - 금리, 인플레이션, 지정학, 무역 전쟁과 관세, 코로나와 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

• 세계의 토포이소머라제 I 억제제 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
• 최종 이용 산업 분석
• 세계의 토포이소머라제 I 억제제 시장 : 성장률 분석
• 세계의 토포이소머라제 I 억제제 시장 실적 : 규모와 성장, 2019-2024년
• 세계의 토포이소머라제 I 억제제 시장 예측 : 규모와 성장, 2024-2029년, 2034년
• 세계의 토포이소머라제 I 억제제 전체 시장(TAM)

제6장 시장 세분화

• 세계의 토포이소머라제 I 억제제 시장 : 유형별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
• 캄프토테신 유도체
• 비캄프토테신
• 세계의 토포이소머라제 I 억제제 시장 : 투여 경로별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
• 경구
• 주사제
• 기타
• 세계의 토포이소머라제 I 억제제 시장 : 용도별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
• 병원
• 클리닉
• 기타
• 세계의 토포이소머라제 I 억제제 시장, 캄프토테신 유도체 하위 세분화, 유형별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
• Irinotecan
• Topotecan
• 세계의 토포이소머라제 I 억제제 시장, 비캄프토테신 하위 세분화, 유형별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
• LMP-400
• Indenoisoquinolines

제7장 지역별·국가별 분석

• 세계의 토포이소머라제 I 억제제 시장 : 지역별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
• 세계의 토포이소머라제 I 억제제 시장 : 국가별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 개요

• 토포이소머라제 I 억제제 시장 : 경쟁 구도
• 토포이소머라제 I 억제제 시장 : 기업 개요
  • Pfizer Inc.
  • Nektar Therapeutics
  • AstraZeneca PLC
  • Novartis AG
  • Fresenius Kabi AG

제31장 기타 주요 기업과 혁신적 기업

• Merck KGaA
• BioNTech SE
• Daiichi Sankyo Company Limited
• Ipsen Pharma S.A.S.
• Purdue Pharma L.P.
• Zymeworks Inc.
• Sagent Pharmaceuticals Inc.
• Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.
• Debiopharm Group SA
• Harbour BioMed Therapeutics Limited
• Bio-Thera Solutions Ltd.
• Gibson Oncology LLC
• TopoGEN Inc.
• DualityBio Inc.
• Iksuda Therapeutics Ltd.

제32장 세계의 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병

제34장 최근의 시장 동향

제35장 시장 잠재력이 높은 국가, 전략

• 토포이소머라제 I 억제제 시장, 2029년 : 새로운 기회를 제공하는 국가
• 토포이소머라제 I 억제제 시장, 2029년 : 새로운 기회를 제공하는 부문
• 토포이소머라제 I 억제제 시장, 2029년 : 성장 전략
  • 시장 동향에 의한 전략
  • 경쟁 전략

제36장 부록

ksm

영문 목차

영문목차

Topoisomerase I inhibitors are a class of therapeutic agents that interfere with the activity of topoisomerase I, an enzyme responsible for relieving the torsional strain that occurs during DNA replication and transcription. These inhibitors work by binding to the enzyme-DNA complex, preventing the re-ligation of DNA strands after the enzyme induces a temporary break. Disruption of topoisomerase I activity leads to the accumulation of DNA damage, ultimately resulting in cell death, particularly in rapidly dividing cells.

The main types of topoisomerase I inhibitors include camptothecin derivatives and non-camptothecin-based inhibitors. Camptothecin derivatives are drugs developed from camptothecin, a natural compound extracted from the Chinese tree Camptotheca acuminata. These inhibitors can be administered through oral, injectable, and other routes and are commonly used in hospitals, clinics, and other healthcare settings.

The topoisomerase I inhibitors market research report is one of a series of new reports from The Business Research Company that provides topoisomerase I inhibitors market statistics, including topoisomerase I inhibitors industry global market size, regional shares, competitors with a topoisomerase I inhibitors market share, detailed topoisomerase I inhibitors market segments, market trends and opportunities, and any further data you may need to thrive in the topoisomerase I inhibitors industry. This topoisomerase I inhibitors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The topoisomerase I inhibitors market size has grown strongly in recent years. It will grow from $5.18 billion in 2024 to $5.49 billion in 2025 at a compound annual growth rate (CAGR) of 6.2%. The growth during the historic period can be attributed to improvements in healthcare infrastructure, rising global healthcare expenditure, higher cancer diagnosis rates, a growing focus on precision oncology, and increased funding for biotech startups.

The topoisomerase I inhibitors market size is expected to see strong growth in the next few years. It will grow to $6.95 billion in 2029 at a compound annual growth rate (CAGR) of 6.0%. The growth during the forecast period can be attributed to the increasing prevalence of cancer, expanding research and development, rising awareness of cancer treatment options, an aging population, and increasing government funding for oncology research. Key trends expected during this period include advancements in genomics and personalized medicine, the development of oral formulations, improved efficacy of combination treatments, the development of generic topoisomerase I inhibitors, and increased public-private collaborations.

The growing prevalence of cancer is expected to significantly boost the topoisomerase I inhibitors market in the near future. Cancer, a group of diseases defined by the uncontrolled growth and spread of abnormal cells, can result in serious health complications, including death. The rise in cancer cases is linked to increasing lifestyle-related risk factors such as poor diet, insufficient physical activity, and tobacco use, all contributing to higher cancer incidence. Topoisomerase I inhibitors are used in cancer treatment by disrupting the DNA replication process in cancer cells, causing DNA damage that halts cell division and induces cell death. For example, in February 2024, the World Health Organization (WHO) projected that by 2050, over 35 million new cancer cases will be diagnosed, a 77% increase from the 20 million expected in 2022. This surge in cancer cases will be a key driver for the growth of the topoisomerase I inhibitors market.

Leading companies in the topoisomerase I inhibitors market are concentrating on developing advanced treatments such as antibody-drug conjugates (ADCs) to overcome drug resistance by leveraging the targeting capabilities of antibodies. ADCs are specialized cancer therapies that attach antibodies to cytotoxic drugs, ensuring that the drug is delivered directly to cancer cells while minimizing damage to healthy tissue. For instance, in July 2024, Zymeworks Inc., a biotechnology company based in Canada, announced that the U.S. Food and Drug Administration (FDA) approved its investigational new drug (IND) application for ZW191. This innovative ADC targets the folate receptor-a (FRa) and delivers a topoisomerase I inhibitor (TOPO1i). ZW191 was developed using the company's proprietary drug conjugate platforms, incorporating the advanced TOPO1i-based payload technology, ZD06519. It primarily targets FRa-expressing tumors, including ovarian and other gynecological cancers, as well as non-small cell lung cancer (NSCLC). The drug was designed with eight drug-antibody ratios (DAR) to optimize safety and efficacy, aiming for a balance of tolerability and therapeutic benefit.

In May 2024, Genmab A/S, a biotechnology company based in Denmark, acquired ProfoundBio for $1.8 billion. This acquisition bolstered Genmab's position in the targeted cancer therapy market, with a particular focus on ovarian and other solid tumors. This move aligns with Genmab's strategy to expand its portfolio of innovative cancer treatments. ProfoundBio, a U.S.-based company, specializes in the manufacturing of topoisomerase I inhibitors.

Major players in the topoisomerase i inhibitors market are Pfizer Inc., Nektar Therapeutics, AstraZeneca PLC, Novartis AG, Fresenius Kabi AG, Merck KGaA, BioNTech SE, Daiichi Sankyo Company Limited, Ipsen Pharma S.A.S., Purdue Pharma L.P., Zymeworks Inc., Sagent Pharmaceuticals Inc., Sigma-Tau Industrie Farmaceutiche Riunite S.p.A., Debiopharm Group SA, Harbour BioMed Therapeutics Limited, Bio-Thera Solutions Ltd., Gibson Oncology LLC, TopoGEN Inc., DualityBio Inc., Iksuda Therapeutics Ltd.

North America was the largest region in the topoisomerase I inhibitors market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in topoisomerase I inhibitors report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the topoisomerase I inhibitors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The topoisomerase I inhibitors market consists of sales of chemotherapy drugs, diagnostic kits, intravenous infusion bags and combination therapy products. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Topoisomerase I Inhibitors Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on topoisomerase i inhibitors market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for topoisomerase i inhibitors ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The topoisomerase i inhibitors market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Camptothecin Derivatives; Non-Camptothecin
• 2) By Route Of Administration: Oral; Injectable; Other Routes Of Administration
• 3) By Application: Hospital; Clinic; Other Applications
• Subsegments:
• 1) By Camptothecin Derivatives: Irinotecan; Topotecan
• 2) By Non-Camptothecin: LMP-400; Indenoisoquinolines
• Companies Mentioned: Pfizer Inc.; Nektar Therapeutics; AstraZeneca PLC; Novartis AG; Fresenius Kabi AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Topoisomerase I Inhibitors Market Characteristics

3. Topoisomerase I Inhibitors Market Trends And Strategies

4. Topoisomerase I Inhibitors Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Topoisomerase I Inhibitors Growth Analysis And Strategic Analysis Framework

• 5.1. Global Topoisomerase I Inhibitors PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Topoisomerase I Inhibitors Market Growth Rate Analysis
• 5.4. Global Topoisomerase I Inhibitors Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Topoisomerase I Inhibitors Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Topoisomerase I Inhibitors Total Addressable Market (TAM)

6. Topoisomerase I Inhibitors Market Segmentation

• 6.1. Global Topoisomerase I Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Camptothecin Derivatives
• Non-Camptothecin
• 6.2. Global Topoisomerase I Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Injectable
• Other Routes Of Administration
• 6.3. Global Topoisomerase I Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital
• Clinic
• Other Applications
• 6.4. Global Topoisomerase I Inhibitors Market, Sub-Segmentation Of Camptothecin Derivatives, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Irinotecan
• Topotecan
• 6.5. Global Topoisomerase I Inhibitors Market, Sub-Segmentation Of Non-Camptothecin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• LMP-400
• Indenoisoquinolines

7. Topoisomerase I Inhibitors Market Regional And Country Analysis

• 7.1. Global Topoisomerase I Inhibitors Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Topoisomerase I Inhibitors Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Topoisomerase I Inhibitors Market

• 8.1. Asia-Pacific Topoisomerase I Inhibitors Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Topoisomerase I Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Topoisomerase I Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Topoisomerase I Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Topoisomerase I Inhibitors Market

• 9.1. China Topoisomerase I Inhibitors Market Overview
• 9.2. China Topoisomerase I Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Topoisomerase I Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Topoisomerase I Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Topoisomerase I Inhibitors Market

• 10.1. India Topoisomerase I Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Topoisomerase I Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Topoisomerase I Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Topoisomerase I Inhibitors Market

• 11.1. Japan Topoisomerase I Inhibitors Market Overview
• 11.2. Japan Topoisomerase I Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Topoisomerase I Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Topoisomerase I Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Topoisomerase I Inhibitors Market

• 12.1. Australia Topoisomerase I Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Topoisomerase I Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Topoisomerase I Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Topoisomerase I Inhibitors Market

• 13.1. Indonesia Topoisomerase I Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Topoisomerase I Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Topoisomerase I Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Topoisomerase I Inhibitors Market

• 14.1. South Korea Topoisomerase I Inhibitors Market Overview
• 14.2. South Korea Topoisomerase I Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Topoisomerase I Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Topoisomerase I Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Topoisomerase I Inhibitors Market

• 15.1. Western Europe Topoisomerase I Inhibitors Market Overview
• 15.2. Western Europe Topoisomerase I Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Topoisomerase I Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Topoisomerase I Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Topoisomerase I Inhibitors Market

• 16.1. UK Topoisomerase I Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Topoisomerase I Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Topoisomerase I Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Topoisomerase I Inhibitors Market

• 17.1. Germany Topoisomerase I Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Topoisomerase I Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Topoisomerase I Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Topoisomerase I Inhibitors Market

• 18.1. France Topoisomerase I Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Topoisomerase I Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Topoisomerase I Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Topoisomerase I Inhibitors Market

• 19.1. Italy Topoisomerase I Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Topoisomerase I Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Topoisomerase I Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Topoisomerase I Inhibitors Market

• 20.1. Spain Topoisomerase I Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Topoisomerase I Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Topoisomerase I Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Topoisomerase I Inhibitors Market

• 21.1. Eastern Europe Topoisomerase I Inhibitors Market Overview
• 21.2. Eastern Europe Topoisomerase I Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Topoisomerase I Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Topoisomerase I Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Topoisomerase I Inhibitors Market

• 22.1. Russia Topoisomerase I Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Topoisomerase I Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Topoisomerase I Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Topoisomerase I Inhibitors Market

• 23.1. North America Topoisomerase I Inhibitors Market Overview
• 23.2. North America Topoisomerase I Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Topoisomerase I Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Topoisomerase I Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Topoisomerase I Inhibitors Market

• 24.1. USA Topoisomerase I Inhibitors Market Overview
• 24.2. USA Topoisomerase I Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Topoisomerase I Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Topoisomerase I Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Topoisomerase I Inhibitors Market

• 25.1. Canada Topoisomerase I Inhibitors Market Overview
• 25.2. Canada Topoisomerase I Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Topoisomerase I Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Topoisomerase I Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Topoisomerase I Inhibitors Market

• 26.1. South America Topoisomerase I Inhibitors Market Overview
• 26.2. South America Topoisomerase I Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Topoisomerase I Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Topoisomerase I Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Topoisomerase I Inhibitors Market

• 27.1. Brazil Topoisomerase I Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Topoisomerase I Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Topoisomerase I Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Topoisomerase I Inhibitors Market

• 28.1. Middle East Topoisomerase I Inhibitors Market Overview
• 28.2. Middle East Topoisomerase I Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Topoisomerase I Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Topoisomerase I Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Topoisomerase I Inhibitors Market

• 29.1. Africa Topoisomerase I Inhibitors Market Overview
• 29.2. Africa Topoisomerase I Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Topoisomerase I Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Topoisomerase I Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Topoisomerase I Inhibitors Market Competitive Landscape And Company Profiles

• 30.1. Topoisomerase I Inhibitors Market Competitive Landscape
• 30.2. Topoisomerase I Inhibitors Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Nektar Therapeutics Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. AstraZeneca PLC Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Fresenius Kabi AG Overview, Products and Services, Strategy and Financial Analysis

31. Topoisomerase I Inhibitors Market Other Major And Innovative Companies

• 31.1. Merck KGaA
• 31.2. BioNTech SE
• 31.3. Daiichi Sankyo Company Limited
• 31.4. Ipsen Pharma S.A.S.
• 31.5. Purdue Pharma L.P.
• 31.6. Zymeworks Inc.
• 31.7. Sagent Pharmaceuticals Inc.
• 31.8. Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.
• 31.9. Debiopharm Group SA
• 31.10. Harbour BioMed Therapeutics Limited
• 31.11. Bio-Thera Solutions Ltd.
• 31.12. Gibson Oncology LLC
• 31.13. TopoGEN Inc.
• 31.14. DualityBio Inc.
• 31.15. Iksuda Therapeutics Ltd.

32. Global Topoisomerase I Inhibitors Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Topoisomerase I Inhibitors Market

34. Recent Developments In The Topoisomerase I Inhibitors Market

35. Topoisomerase I Inhibitors Market High Potential Countries, Segments and Strategies

• 35.1 Topoisomerase I Inhibitors Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Topoisomerase I Inhibitors Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Topoisomerase I Inhibitors Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer